Game Plan Financial Advisors LLC Acquires 58 Shares of Eli Lilly and Company $LLY

Game Plan Financial Advisors LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 4.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,328 shares of the company’s stock after purchasing an additional 58 shares during the quarter. Game Plan Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $1,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Weaver Capital Management LLC lifted its stake in Eli Lilly and Company by 3.0% in the 2nd quarter. Weaver Capital Management LLC now owns 3,589 shares of the company’s stock worth $2,798,000 after purchasing an additional 104 shares in the last quarter. MFA Wealth Services lifted its stake in Eli Lilly and Company by 3.5% in the 2nd quarter. MFA Wealth Services now owns 1,362 shares of the company’s stock worth $1,062,000 after purchasing an additional 46 shares in the last quarter. Leo Wealth LLC lifted its stake in Eli Lilly and Company by 24.1% in the 2nd quarter. Leo Wealth LLC now owns 4,106 shares of the company’s stock worth $3,192,000 after purchasing an additional 798 shares in the last quarter. MSH Capital Advisors LLC lifted its stake in Eli Lilly and Company by 1.5% in the 2nd quarter. MSH Capital Advisors LLC now owns 1,381 shares of the company’s stock worth $1,076,000 after purchasing an additional 20 shares in the last quarter. Finally, Wealth Advisors Northwest LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $239,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on LLY shares. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. Finally, Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the company an “overweight” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $948.56.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger purchased 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $854.40 on Friday. The stock has a market cap of $808.66 billion, a PE ratio of 55.84, a PEG ratio of 1.18 and a beta of 0.47. The company’s fifty day moving average is $740.99 and its 200 day moving average is $766.49. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.